Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - NYSE Other stock markets 04:01:32 2026-06-29 pm EDT			After hours 08:00:00 pm
1,229.93 ^USD	+1.81%		1,229.00	-0.08%

04:14am	Eli Lilly transfers commercialization rights for breast cancer drug in China amid generic competition	RE
01:59am	An exuberant quarter for equities, but not an irrational one?

Eli Lilly, InSilico Strike AI Drug Discovery Deal That Could Be Worth Up to $2.75 Billion

Published on 03/29/2026 at 10:21 pm EDT - Modified on 03/29/2026 at 10:22 pm EDT

Dow Jones

ELI LILLY AND COMPANY

+1.81%

INSILICO MEDICINE CAYMAN TOPCO

-4.25%

By Jason Chau

Eli Lilly has signed a drug discovery deal with InSilico that the Hong Kong-listed biotech firm says could be valued at as much as $2.75 billion.

The partnership is the latest in a string of tie-ups between pharma majors and Chinese firms, and grants Lilly exclusive worldwide rights to a portfolio of programs across multiple therapeutic areas.

InSilico will receive an upfront payment of $115 million, and is eligible for additional milestone payments that could put the total deal value at about $2.75 billion, it said in a filing.

The companies will also work on multiple research-and-development programs focused on targets selected by Lilly, and using InSilico's Pharma.AI platforms.

Shares of InSilico, which specializes in integrating AI and automation in drug discoveries, surged 10% in early trade on Monday.

Write to Jason Chau at jason.chau@wsj.com

(END) Dow Jones Newswires

03-29-26 2220ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
	ELI LILLY AND COMPANY	1,229.93USD	+1.81%	+11.60%	1,097B
	INSILICO MEDICINE CAYMAN TOPCO	39.62HKD	-4.25%	-7.60%	3.02B

Latest news about Eli Lilly and Company

04:14am	Eli Lilly transfers commercialization rights for breast cancer drug in China amid generic competition	RE
01:59am	An exuberant quarter for equities, but not an irrational one?
01:36am	Innovent Biologics, Inc. and Eli Lilly and Company Enter Commercialization Agreement for Verzenios (Abemaciclib) in Mainland China	CI
Jun. 29	Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program	MT
Jun. 29	Lilly, Regeneron selected for US program to review new manufacturing plants faster	RE
Jun. 29	FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports	RE
Jun. 29	Eli Lilly, Abu Dhabi's Health Department Enter MoU to Manage Obesity, Alzheimer's Disease	MT
Jun. 29	Emirati Shares End Lower as US-Iran Exchange Fresh Strikes	MT
Jun. 29	FDA set to review Sandoz's generic GLP-1s	RE
Jun. 29	Sandoz's Applications for Mounjaro, Zepbound Generics Accepted for FDA Review	DJ
Jun. 29	Sandoz New Drug Applications for Generic Tirzepatide Versions Accepted for US FDA Review	MT
Jun. 29	Pfizer, Innovent GLP-1 drugs clear China insurance hurdle	RE
Jun. 26	Health Care Up on Rotation Into Laggards -- Health Care Roundup	DJ
Jun. 26	Eli Lilly And Company Receives Positive Opinion From CHMP For Jaypirca For Treatment Of Adults With Chronic Lymphocytic Leukemia Across All Lines Of Therapy	CI
Jun. 26	Eli Lilly's Blood Cancer Therapy Recommended for EU Approval	MT

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).

Employees

50,000

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company